NYSE:EBS Emergent Biosolutions (EBS) Stock Price, News & Analysis $8.48 +0.12 (+1.37%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$8.40 -0.09 (-1.06%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Emergent Biosolutions Stock (NYSE:EBS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Emergent Biosolutions alerts:Sign Up Key Stats Today's Range$8.35▼$8.6050-Day Range$7.84▼$9.5052-Week Range$5.61▼$14.06Volume986,645 shsAverage Volume718,463 shsMarket Capitalization$438.17 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingHold Company Overview Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs. Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal. The company invests in research and development to expand its pipeline of vaccines and therapeutics, with particular emphasis on next-generation platforms and novel delivery approaches. Emergent operates research, development and manufacturing facilities in North America, Europe and Asia. Its primary U.S. manufacturing sites in Maryland and Michigan produce both licensed products and countermeasures under contract, while additional sites and partnerships support global distribution. Through a network of collaborations and supply agreements, Emergent serves government health agencies, commercial customers and international markets to ensure availability of its critical medical products. Founded in 1998 (originally as BioPort) and renamed Emergent BioSolutions in 2004, the company is led by President and Chief Executive Officer Robert G. Kramer Jr. Under his leadership, Emergent has expanded its contract manufacturing footprint, strengthened its commercial portfolio and advanced strategic initiatives in pandemic preparedness. The company remains focused on leveraging its expertise in biodefense and public health to address evolving global health challenges.AI Generated. May Contain Errors. Read More Emergent Biosolutions Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreEBS MarketRank™: Emergent Biosolutions scored higher than 50% of companies evaluated by MarketBeat, and ranked 681st out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingEmergent Biosolutions has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialEmergent Biosolutions has a consensus price target of $12.00, representing about 41.4% upside from its current price of $8.49.Amount of Analyst CoverageEmergent Biosolutions has only been the subject of 2 research reports in the past 90 days.Read more about Emergent Biosolutions' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent Biosolutions is 8.45, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent Biosolutions is 8.45, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.06.Price to Book Value per Share RatioEmergent Biosolutions has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Emergent Biosolutions' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.14% of the float of Emergent Biosolutions has been sold short.Short Interest Ratio / Days to CoverEmergent Biosolutions has a short interest ratio ("days to cover") of 18.42, which indicates bearish sentiment.Change versus previous monthShort interest in Emergent Biosolutions has recently increased by 1.36%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEmergent Biosolutions does not currently pay a dividend.Dividend GrowthEmergent Biosolutions does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.23 News SentimentEmergent Biosolutions has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Emergent Biosolutions this week, compared to 3 articles on an average week.Search Interest6 people have searched for EBS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Emergent Biosolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $518,312.00 in company stock.Percentage Held by Insiders6.00% of the stock of Emergent Biosolutions is held by insiders.Percentage Held by Institutions78.40% of the stock of Emergent Biosolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Emergent Biosolutions' insider trading history. Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent Biosolutions and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EBS Stock News HeadlinesEmergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health AuthorizationMay 20, 2026 | finance.yahoo.comEmergent BioSolutions to Participate in Upcoming Investor ConferencesMay 20, 2026 | globenewswire.comOne algorithm, 17 years, nearly 2,000% total returnsA physicist in Dublin claims his AI algorithm has beaten the market for 17 consecutive years - with nearly 2,000% total returns and only one losing year across two decades of crises. Porter Stansberry flew to Ireland to investigate the claim firsthand. The result is a new investigative documentary called 'Investigating Project Prophet,' available to stream now at no cost.May 24 at 1:00 AM | Porter & Company (Ad)Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]May 18, 2026 | globenewswire.comHantavirus cases spark surge in pharma and biotech stocks — here's whyMay 11, 2026 | cnbc.comSujata Tyagi Dayal Sells 13,761 Shares of Emergent Biosolutions (NYSE:EBS) StockMay 5, 2026 | insidertrades.comEmergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights: Strong Revenue and Strategic ...May 2, 2026 | finance.yahoo.comEmergent BioSolutions Earnings Call Highlights Turnaround MomentumMay 1, 2026 | tipranks.comSee More Headlines EBS Stock Analysis - Frequently Asked Questions How have EBS shares performed this year? Emergent Biosolutions' stock was trading at $12.35 on January 1st, 2026. Since then, EBS stock has decreased by 31.3% and is now trading at $8.4850. How were Emergent Biosolutions' earnings last quarter? Emergent Biosolutions Inc. (NYSE:EBS) posted its earnings results on Thursday, April, 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of ($0.25) by $0.46. The biopharmaceutical company had revenue of $156.10 million for the quarter, compared to analysts' expectations of $145 million. Emergent Biosolutions had a positive trailing twelve-month return on equity of 10.76% and a negative net margin of 1.27%. Read the conference call transcript. Is Emergent Biosolutions doing a stock buyback? Emergent Biosolutions' board authorized a stock repurchase program on Monday, March 31st 2025, which permits the company to repurchase $50,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 19% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its stock is undervalued. Who are Emergent Biosolutions' major shareholders? Emergent Biosolutions' top institutional shareholders include Dimensional Fund Advisors LP (5.34%), Renaissance Technologies LLC (1.27%), Values First Advisors Inc. (0.60%) and Cetera Investment Advisers (0.44%). Insiders that own company stock include Coleen Glessner, Donald W Degolyer, Neal Franklin Fowler, Sujata Tyagi Dayal, Ronald Richard, Keith Katkin and Kathryn C Zoon. View institutional ownership trends. How do I buy shares of Emergent Biosolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Emergent Biosolutions own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent Biosolutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA) and Moderna (MRNA). Company Calendar Last Earnings4/30/2026Today5/24/2026Jefferies Global Healthcare Conference 20266/03/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/08/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 EBS's financial health is in the Green zone, according to TradeSmith. EBS has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNYSE:EBS CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees2,420Year FoundedN/APrice Target and Rating Average Price Target for Emergent Biosolutions$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+41.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$52.60 million Net Margins-1.27% Pretax Margin0.52% Return on Equity10.76% Return on Assets4.22% Debt Debt-to-Equity Ratio1.10 Current Ratio4.29 Quick Ratio2.08 Sales & Book Value Annual Sales$742.90 million Price / Sales0.59 Cash Flow$3.67 per share Price / Cash Flow2.31 Book Value$10.13 per share Price / Book0.84Miscellaneous Outstanding Shares51,640,000Free Float48,545,000Market Cap$438.17 million OptionableOptionable Beta2.33 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NYSE:EBS) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent Biosolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent Biosolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
